![April 2022: Single-dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis](https://icap.columbia.edu/wp-content/uploads/unnamed-3-1080x675.jpg)
South Africa
![April 2022: Single-dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis](https://icap.columbia.edu/wp-content/uploads/unnamed-3-1080x675.jpg)
Women’s Perceptions Of HIV- And Sexuality-Related Stigma in Relation to Prep: Qualitative Findings from The Masibambane Study, Durban, South Africa
Authors: S Bergam, A D Harrison, N Benghu, S Khumalo, N Tesfay, T Exner, L Miller, C Dolezal, J Hanass-Hancock, S Hoffman Daily oral pre-exposure prophylaxis (PrEP) offers effective HIV prevention. In South Africa, PrEP is publicly available, but use among young women...![February 2022: Dolutegravir as First- or Second-line Treatment for HIV-1 Infection in Children](https://icap.columbia.edu/wp-content/uploads/istock1-1080x675.png)
February 2022: Dolutegravir as First- or Second-line Treatment for HIV-1 Infection in Children
Article and Study Summary: Dolutegravir as First- or Second-line Treatment for HIV-1 Infection in Children Published in: New England Journal of Medicine 2021,385(27):2531-2543. https://www.nejm.org/doi/full/10.1056/NEJMoa2108793 Authors: Turkova A, White E, Mujuru HA,...![Quality Improvement Capacity for Impact Project (QICIP) Report](https://icap.columbia.edu/wp-content/uploads/Untitled-design-10-1080x675.png)
Quality Improvement Capacity for Impact Project (QICIP) Report
The Quality Improvement Capacity for Impact Project (QICIP), funded by PEPFAR through the U.S. Health Resources and Services Administration (HRSA), supported projects in 11 countries that enhanced local capacity to design, implement, evaluate, document, and sustain a...![November/December 2021: Treating Depression and Improving Adherence in HIV Care with Task-Shared Cognitive Behavioural Therapy in Khayelitsha, South Africa: A Randomized Controlled Trial](https://icap.columbia.edu/wp-content/uploads/18249514983_433cf50aca_o-1080x675.png)